A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

30 treated chronic HIV-1 infected patients with CD4+ cell counts above 450 cells/ mm3 will be randomized 1:2 to receive placebo (n=10) or vaccine (n=20) at week 0, 4 and 16 and will be observed at the Investigation Unit of the study site for one hour following vaccination. At week 24 they will stop their HAART until the end of the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)

NCT00117429

HIV Infections

COMPLETED PHASE1

Effectiveness of Antiretroviral Therapy During Acute HIV Infection

NCT00705926

HIV Infections

COMPLETED PHASE1

Study of KP-1461 for the Treatment of HIV Positive Patients Who Have Failed Multiple HAART Regimens

NCT00129194

HIV Infections

COMPLETED PHASE1

REal-Life Cohort With DOlutegravir + LAmivudina

NCT04638686

HIV-1-infection

COMPLETED

Effects of Intensive cART During Acute/Early HIV Infection

NCT01154673

Acute HIV Infection

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccine group

Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef) (MVA HIV-B)

Group Type EXPERIMENTAL

Vaccination

Intervention Type DRUG

* Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)

-\~ 1 x 10e8 pfu/ml
* 3 immunisations at week 0, 4 and 16

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

3 immunisations at week 0, 4 and 16

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vaccination

* Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)

-\~ 1 x 10e8 pfu/ml
* 3 immunisations at week 0, 4 and 16

Intervention Type DRUG

Placebo

3 immunisations at week 0, 4 and 16

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is ≥ 18 years of age;
* Voluntarily signed informed consent;
* Patient is male, or female with negative pregnancy test prior to enrolment;
* Patient has a proven HIV-1 infection (with positive antibodies against HIV-1 and a detectable plasma HIV-1 RNA);
* Patient must be on stable treatment with HAART for at least 6 months (HAART is defined as an antiretroviral regimen consisting of at least three registered antiretroviral agents\*);
* Mean of all measured CD4+ cell counts during the 6 months prior to the start of HAART must be above or equal to 200 cells/ mm3
* Current CD4+ cell count must be at least 450 cells/ mm3;
* HIV-RNA must be below 50 copies/ mL for the last 6 months prior to inclusion, during at least two measurements (occasional so called 'blips' up to 50 copies/mL are permitted);
* Patient is one of the following: not sexually active, or a heterosexually active female, agreeing to use condoms with her partner from 14 days prior to the first vaccination until 4 months after the last, even though using another method of contraception, and willing to undergo pregnancy tests during screening and prior to each vaccination, or a male, agreeing to use condoms with his partner from the day of the first vaccination until 4 months after the last vaccination.

Exclusion Criteria

* Treatment with a non-HAART regimen of antiretroviral agents prior to the start of HAART;
* History of a CDC class C event (see Appendix);
* Interruption of HAART during the course of the study which is expected at the time of inclusion;
* History of exposure \<20 years ago to any poxvirus based vaccine;
* Patient is female and has a positive pregnancy test or the wish of pregnancy:
* Active opportunistic infection, or any active infection or malignancy within 30 days prior to screening visit;
* Therapy with immunomodulatory agents, including cytokines (e.g. IL2) and gamma globulin, or cytostatic chemotherapy within 90 days prior to screening visit;
* History of allergy to any vaccine component;
* Use of anti-coagulant medication;
* Use of any investigational drug during the 90 days prior to study entry;
* Previous failure to antiretroviral and/or mutations conferring genotypic resistance to antiretroviral therapy
* Any other condition which, in the opinion

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No